Regeneron loses bid to block Amgen's launch of Eylea biosimilar
Amgen will release its biosimilar version of Regeneron's Eylea following a U.S. appeals court ruling in its favor, per a Reuters report, which attributed the news to an Amgen spokesperson.
The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
Eylea is used to treat eye diseases like macular degeneration, macular edema and retinopathy.
“We continue to believe that Amgen is infringing our patent rights, and today's decision denying our request for a temporary injunction is not the final word in this litigation," Regeneron said in a statement.
[Related news: FDA approves 2 Eylea biosimilars]
The report said that the Amgen spokesperson said the company will make its biosimilar, Pavblu, available to patients "as quickly as possible to help expand access to affordable and effective treatment."
The report also noted that Regeneron sued Amgen for infringing dozens of its patents related to Eylea. A West Virginia federal judge last month rejected Regeneron's request to block Amgen's launch of Pavblu while Regeneron pursues its patent claims against the company in the ongoing case.
[Related news: Regeneron gets FDA nod for updated Eylea label]